Yu-Waye Chu

2021

In 2021, Yu-Waye Chu earned a total compensation of $6.5M as Chief Medical Officer at Fate Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$172,000
Option Awards$500,000
Salary$430,000
Stock Awards$5,375,416
Total$6,477,416

Chu received $5.4M in stock awards, accounting for 83% of the total pay in 2021.

Chu also received $172K in non-equity incentive plan, $500K in option awards and $430K in salary.

Rankings

In 2021, Yu-Waye Chu's compensation ranked 1,947th out of 12,415 executives tracked by ExecPay. In other words, Chu earned more than 84.3% of executives.

ClassificationRankingPercentile
All
1,947
out of 12,415
84th
Division
Manufacturing
737
out of 5,505
87th
Major group
Chemicals And Allied Products
282
out of 2,375
88th
Industry group
Drugs
241
out of 2,096
89th
Industry
Biological Products, Except Diagnostic Substances
73
out of 449
84th
Source: SEC filing on April 25, 2022.

Chu's colleagues

We found five more compensation records of executives who worked with Yu-Waye Chu at Fate Therapeutics in 2021.

2021

J Wolchko

Fate Therapeutics

Chief Executive Officer

2021

Mark Plavsic

Fate Therapeutics

Chief Technology Officer

2021

Bahram Valamehr

Fate Therapeutics

Chief Research and Development Officer

2021

Cindy Tahl

Fate Therapeutics

General Counsel

2021

Edward Dulac

Fate Therapeutics

Chief Financial Officer

News

You may also like